(1R,6R)-2-oxa-5,8-diazabicyclo[4.3.0]nonane | 138026-94-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: (1R,6R)-2-oxa-5,8-diazabicyclo[4.3.0]nonane
• 英文别名: trans-2-Oxa-5,8-diazabicyclo[4.3.0]nonane；Pyrrolo[3,4-b]-1,4-oxazine, octahydro-, trans-；(4aR,7aR)-2,3,4,4a,5,6,7,7a-octahydropyrrolo[3,4-b][1,4]oxazine
• CAS: 138026-94-5
• 化学式: C₆H₁₂N₂O
• 分子量: 128.174
• InChiKey: UMIZTIYZNFUATK-PHDIDXHHSA-N

物化性质

• 沸点：
  228.7±25.0 °C(Predicted)
• 密度：
  1.035±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  33.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1R,6R)-2-oxa-5,8-diazabicyclo[4.3.0]nonane 在 20percent aq. HCl 作用下， 以 乙腈 为溶剂， 生成 7-[(4aS,7aS)-2,3,4,4a,5,6,7,7a-octahydropyrrolo[3,4-b][1,4]oxazin-6-ium-6-yl]-6-fluoro-4-oxo-1-(1,3-thiazol-2-yl)-1,8-naphthyridine-3-carboxylic acid;chloride
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of Novel 7-Substituted 1,4-Dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic Acids as Antitumor Agents. Part 1

  摘要：

  In an attempt to search for clinically useful antitumor agents, we have discovered that a series of 1,1-disubstituted-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids possessed moderate cytotoxic activity.,We investigated the structure-activity relationships in this series of compounds by changing N-1 and C-7 positions and the core ring structure itself and evaluated the synthesized compounds against several murine and human tumor cell lines. These modifications led us to the following findings. (1) The 2-thiazolyl group at the N-1 position of the naphthyridine structure is the best substituent for antitumor activity. (2) Regarding core ring structure, the naphthyridine derivative is the most active followed by pyridopyrimidine analogue. (3) At the C-7 position, -aminopyrrolidine derivatives are more effective than other amines or thioether derivatives. Finally, the trans-3-amino-4-methoxypyrrolidinyl derivative (43j), and the 3-amino-3-methylpyrrolidinyl derivative (43f) as well as 3-aminopyrrolidinyl derivative (AT-3639, 1) were determined to be effective in in vitro and in vivo antitumor assays, and their activity was comparable to that of etoposide.

  DOI：

  10.1021/jm010057b
• 作为产物：
  描述：

  (1R,6R)-2-oxa-5,8-diazabicyclo[4.3.0]nonane dihydrobromide 、 氢氧化钾 250.0 ℃ 、2.67 kPa 条件下， 以490 mg (76.6% of theory) of (1R,6R)-2-oxa-5,8-diazabicyclo[4.3.0]nonane are obtained as a viscous oil, which的产率得到(1R,6R)-2-oxa-5,8-diazabicyclo[4.3.0]nonane
  参考文献：
  名称：

  Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic

  摘要：

  本发明涉及使用7位被2-氧杂-5,8-二氮杂双环[4.3.0]-壬-8-基基团取代的喹诺酮和萘啶酮羧酸衍生物以及它们的药用水合物和/或盐，用于治疗幽门螺杆菌感染和相关的胃十二指肠疾病。

  公开号：

  US06133260A1

文献信息

• [EN] NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION<br/>[FR] NOUVEAUX DÉRIVÉS D'AMINOPYRIDINE PRÉSENTANT UNE ACTION INHIBITRICE SÉLECTIVE DE L'AURORA A
  申请人：BANYU PHARMA CO LTD

  公开号：WO2010111057A1

  公开（公告）日：2010-09-30

  The present invention relates to a compound of Formula (I): wherein: n is 0 or 1; X is O or CH2; R1 is H or C1-2 alkyl; R2 is H or C1-3 alkyl; R3 and R4 are each independently H or C1-2 alkyl, where the alkyl may be substituted with one to three of the same or different substituents selected from R10 R5 is H or OCH3; R10 is F or Cl; or a pharmaceutically acceptable salt or ester thereof.

  本发明涉及一种化合物，其化学式为（I）：其中：n为0或1；X为O或CH2；R1为H或C1-2烷基；R2为H或C1-3烷基；R3和R4分别独立地为H或C1-2烷基，其中烷基可能被选自R10的一个到三个相同或不同的取代基取代；R5为H或OCH3；R10为F或Cl；或其药学上可接受的盐或酯。
• Chinolon- und Naphthyridon-Carbonsäurederivate als antibakterielles Mittel
  申请人：BAYER AG

  公开号：EP0550903A1

  公开（公告）日：1993-07-14

  Chinolon- und Naphthyridon-carbonsäure-Derivate der Formel (I) in welcher Bfür einen Rest der Formeln steht in welcher Yfür O oder CH₂ und R³für C₂-C₅-Oxoalkyl, CH₂-CO-C₆H₅, CH₂CH₂CO₂R', -CH=CH-CO₂R' oder CH₂CH₂-CN, worin R'Wasserstoff oder C₁-C₃-Alkyl bedeutet, R⁴für H, C₁-C₃-Alkyl, 5-Methyl-2-oxo-1,3-dioxol-4-yl-methyl, C₂-C₅-Oxoalkyl, CH₂-CO-C₆H₅, CH₂CH₂CO₂R', -CH=CH-CO₂R' oder CH₂CH₂-CN, sowie diese enthaltende antibakterielle Mittel und Futterzusatzstoffe.

  化合物式（I）中的喹诺酮和萘啶酮羧酸衍生物，其中B代表以下公式的一个基团：公式中Y代表O或CH₂，R³代表C₂-C₅氧代烷基，CH₂-CO-C₆H₅，CH₂CH₂CO₂R'，-CH=CH-CO₂R'或CH₂CH₂-CN，其中R'代表氢或C₁-C₃烷基，R⁴代表H，C₁-C₃烷基，5-甲基-2-氧代-1,3-二氧杂环戊烷-4-基甲基，C₂-C₅氧代烷基，CH₂-CO-C₆H₅，CH₂CH₂CO₂R'，-CH=CH-CO₂R'或CH₂CH₂-CN。以及包含这些化合物的抗菌剂和饲料添加剂。
• Enantiomerenreine 2-Oxa-5,8-diazabicyclo (4.3.0)nonane sowie Verfahren zu ihrer Herstellung
  申请人：BAYER AG

  公开号：EP0551653A1

  公开（公告）日：1993-07-21

  Die Erfindung betrifft enantiomerenreine 2-Oxa-5,8-diazabicyclo[4.3.0]nonane der Formel (I) in welcher R¹ und R² die in der Beschreibung angegebene Bedeutung haben und Verfahren zu ihrer Herstellung.

  这项发明涉及纯对映体的2-Oxa-5,8-二氮杂双环[4.3.0]壬烷（I）的制备方法，其中R¹和R²具有描述中所述的含义。
• USE OF 7-(2-OXA-5,8-DIAZABICYLCO&lsqb;4.3.0&rsqb;NON-8-YL)-QUINOLONE CARBOXYLIC ACID AND NAPHTHYRIDON CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF HELIOBACTER PYLORI INFECTIONS AND ASSOCIATED GASTRODUODENAL DISEASES
  申请人：Bayer Aktiengesellschaft

  公开号：US06432948B1

  公开（公告）日：2002-08-13

  The invention relates to the use of quinolone- and naphthyridonecarboxylic acid derivatives, which are substituted in the 7-position by a 2-oxa-5,8-diazabicyclo[4.3.0]-non-8-yl) radical, and their pharmaceutically utilizable hydrates and/or salts for the therapy of Helicobacter pylori infections and the gastroduodenal disorders associated therewith.

  本发明涉及使用在7位上被2-氧杂-5,8-二氮杂双环[4.3.0]壬-8-基基团取代的喹诺酮和萘啶酮羧酸衍生物及其药用水合物和/或盐，用于治疗幽门螺杆菌感染和与之相关的胃十二指肠疾病。
• NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION
  申请人：Iwama Toshiharu

  公开号：US20120015940A1

  公开（公告）日：2012-01-19

  The present invention relates to a compound of Formula (I): wherein: n is 0 or 1; X is O or CH 2 ; R 1 is H or C 1-2 alkyl; R 2 is H or C 1-3 alkyl; R 3 and R 4 are each independently H or C 1-2 alkyl, where the alkyl may be substituted with one to three of the same or different substituents selected from R 10 R 5 is H or OCH 3 ; R 10 is F or Cl; or a pharmaceutically acceptable salt or ester thereof.

  本发明涉及一种公式（I）的化合物：其中：n为0或1；X为O或CH2；R1为H或C1-2烷基；R2为H或C1-3烷基；R3和R4均独立地为H或C1-2烷基，其中烷基可以被一个到三个相同或不同的取代基R10取代；R5为H或OCH3；R10为F或Cl；或其药学上可接受的盐或酯。